by Sara M. Nolte | May 28, 2020
Cancer immunotherapy is so hot right now. Signals bloggers have covered CAR T cells (here and here), but haven’t given some other exciting immunotherapies their time to shine. I aim to correct that. A normal part of the immune system, checkpoints are a mechanism to...
by David Kent | May 21, 2020
Over the past four weeks, I’ve discussed numerous aspects of gene therapy in an attempt to convey my excitement for this field moving forward. The convergence of numerous advances in basic biology (as described here and here) and clinical trials (as explained here and...
by David Kent | May 14, 2020
The second post in this series on gene therapy and blood stem cells might give readers a small sense of the absolutely enormous research investment (time, money, people, etc.) required to find a way to expand blood stem cells for therapeutic purposes. Ever since the...
by David Kent | May 6, 2020
As mentioned in the introductory post to this series on blood stem cell gene therapy, several significant issues existed with the first set of clinical trials in the gene therapy world. It became abundantly clear that simply delivering the gene target on its own would...
by David Kent | Apr 30, 2020
Blood stem cells are the fundamental component of regenerative medicine applications involving the blood and immune system. Despite significant efforts and investment, the research community has largely failed to maintain fully functional blood stem cells for...
by David Kent | Apr 21, 2020
Over the coming weeks, I will be writing a series of blog entries on gene therapy using blood stem cells as a base cellular product. In the last few years we have witnessed an incredible return to the headlines for gene therapy now that safer, more accurate tools have...
Comments